Cargando…

The molecular targets of approved treatments for pulmonary arterial hypertension

Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humbert, Marc, Ghofrani, Hossein-Ardeschir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://www.ncbi.nlm.nih.gov/pubmed/26219978 http://dx.doi.org/10.1136/thoraxjnl-2015-207170

Ejemplares similares

The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
por: Weiss, Astrid, et al.
Publicado: (2019)

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
por: Humbert, Marc, et al.
Publicado: (2017)

Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
por: Lang, Irene, et al.
Publicado: (2017)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension
por: Rai, Nabham, et al.
Publicado: (2022)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension
por: Grimminger, Jan, et al.
Publicado: (2017)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
por: Sydykov, Akylbek, et al.
Publicado: (2021)

Analysis of Electrocardiographic Criteria of Right Ventricular Hypertrophy in Patients with Chronic Thromboembolic Pulmonary Hypertension before and after Balloon Pulmonary Angioplasty
por: Ley, Lukas, et al.
Publicado: (2023)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Mechanisms of disease: pulmonary arterial hypertension
por: Schermuly, Ralph T., et al.
Publicado: (2011)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled
por: Hemnes, Anna R., et al.
Publicado: (2017)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension
por: Sklepkiewicz, Piotr, et al.
Publicado: (2011)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Screening for pulmonary arterial hypertension in systemic sclerosis
por: Weatherald, Jason, et al.
Publicado: (2019)

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
por: Rhodes, Christopher J, et al.
Publicado: (2017)

Incidence and prognostic significance of malignant arrhythmias during (repetitive) Holter electrocardiograms in patients with pulmonary hypertension
por: Bandorski, Dirk, et al.
Publicado: (2023)

Chronic thromboembolic pulmonary hypertension
por: Kim, Nick H., et al.
Publicado: (2019)

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension
por: Weatherald, Jason, et al.
Publicado: (2023)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension
por: Perros, Frédéric, et al.
Publicado: (2021)

Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension
por: Le Ribeuz, Hélène, et al.
Publicado: (2020)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021)

Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension
por: Tiede, Henning, et al.
Publicado: (2015)

Screening strategies for pulmonary arterial hypertension
por: Kiely, David G, et al.
Publicado: (2019)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_917tsfchq37tt0vpj5s22bmv15